Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 46.1% in August

by · The Markets Daily

Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) saw a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 32,907 shares, a drop of 46.1% from the July 30th total of 61,079 shares. Based on an average trading volume of 464,283 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company’s shares are sold short.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BFRI shares. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Our Latest Stock Report on BFRI

Biofrontera Stock Down 0.9%

Shares of Biofrontera stock opened at $1.57 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company has a 50-day moving average of $1.19 and a 200 day moving average of $1.02. The firm has a market cap of $23.39 million, a price-to-earnings ratio of -3.50 and a beta of 0.78. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.61.

Biofrontera (NASDAQ:BFRI – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $9.50 million. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. As a group, sell-side analysts anticipate that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. increased its stake in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 51.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 976,448 shares of the company’s stock after buying an additional 332,055 shares during the period. Biofrontera accounts for about 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent filing with the Securities & Exchange Commission. 10.08% of the stock is currently owned by hedge funds and other institutional investors.

Biofrontera Company Profile

(Get Free Report)

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.

See Also